We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ferrex | LSE:FRX | London | Ordinary Share | GB00B649J414 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.45 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jun 2019 to Jun 2024
The U.S. Department of Justice filed civil charges Wednesday alleging that Forest Laboratories Inc. (FRX) improperly marketed two of its antidepressant drugs for use in children and paid kickbacks to encourage doctors to prescribe the drugs.
The government's legal complaint, filed in a Massachusetts federal court, alleges that Forest misled doctors and consumers by failing to disclose a medical study that determined the company's antidepressant drugs were ineffective for pediatric use.
Despite the negative study, Forest promoted its antidepressant drugs Celexa and Lexapro for use with children, prosecutors said.
Prosecutors also alleged that Forest lavished doctors with cash payments, expensive meals and other valuables to induce them to prescribe its antidepressant drugs Celexa and Lexapro.
-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com
1 Year Ferrex Chart |
1 Month Ferrex Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
